UPDATE : Monday, September 7, 2020
상단여백
Tecentriq becomes 1st immunotherapy OKed for specific breast cancer by Kim Yun-mi 2019-03-13 12:43
‘Pay more attention to lipid control in stroke patients’ by Kim Yun-mi 2019-03-12 11:32
When will NOAC reversal agents be available in Korea? by Kim Yun-mi 2019-03-07 15:52
Biogen seeks gene therapy pipeline for rare eye disease by Kim Yun-mi 2019-03-06 14:41
Regulator expands XGEVA’s indication for use by multiple myeloma patients by Kim Yun-mi 2019-03-04 16:02
라인
Korea’s drug exports hit record high in 2018, industry group says by Kim Yun-mi 2019-02-27 13:08
‘Heat-not-burn cigarettes as risky as traditional ones’ by Kim Yun-mi 2019-02-26 15:45
Korean Society of Cardiometabolic Syndrome goes international by Kim Yun-mi 2019-02-25 14:35
Lung cancer 2nd treatment Alunbrig likely to get insurance coverage by Kim Yun-mi 2019-02-25 14:06
Will first-ever treatment for nonalcoholic fatty liver arrive? by Kim Yun-mi 2019-02-22 15:29
라인
DPP-4 inhibitors raise bullous pemphigoid risk in diabetic patients: study by Kim Yun-mi 2019-02-21 15:13
Xtandi adds indication for non-metastatic castration-resistant prostate cancer by Kim Yun-mi 2019-02-21 15:10
84% of breast cancer patients are in working age in Korea by Kim Yun-mi 2019-02-20 14:52
[News Focus] Will MSD’s new antidiabetic SGLT-2 inhibitor prove effective? by Kim Yun-mi 2019-02-19 14:31
‘Hair loss drug Propesia works well for Koreans in long term’ by Kim Yun-mi 2019-02-18 16:38
라인
Hanmi’s RaboneD dominates osteoporosis therapy market by Kim Yun-mi 2019-02-18 14:23
MSD leads rapidly growing antidiabetic DPP-4 inhibitors market by Kim Yun-mi 2019-02-15 14:31
Direct-acting antivirals reduce death risk for hepatitis C patients: study by Kim Yun-mi 2019-02-14 14:59
Blood-thinning NOAC market expands 30% in 2018 by Kim Yun-mi 2019-02-14 12:12
Price cut, expanded indication to prop up cholesterol-reducing PCSK9 inhibitors by Kim Yun-mi 2019-02-13 16:11
여백
여백
여백
Back to Top